The ER&D slug continues - haunts

TATAELXSI

's Q1 results were a reality check for investors betting on premium valuations. Sales dropped 3.7% to ₹892 crores while EBITDA plunged 26% to ₹187 crores. Margins compressed sharply from 27% to 21%, squeezed by rising costs and slower R&D work. The heavy auto exposure (~50% of revenue) backfired as OEMs like JLR hit pause on programs amid U.S. trade uncertainty. The stock fell 7% post-results, with brokerages downgrading on weak deal momentum and macro headwinds. Management promises recovery from Q2, but with demand sluggish across auto, media, and healthcare, visibility remains poor. Here's the problem: at nearly 50x P/E, the market was pricing in acceleration. Instead, it got contraction. The concentrated client base that worked during good times became a liability when sectors turned cautious. Tata Elxsi built its premium on consistent execution and margin expansion. Now it has to re-earn that trust. Until deal momentum picks up and diversification improves, caution beats conviction here.